On Jan. 24, Johnson & Johnson (NYSE:JNJ) released fiscal year 2005 earnings for the period ended Dec. 31, 2005.
- Sales in JNJ's medical devices and diagnostics segment were up 13% for the year.
- The company's research expense for the year increased by 14.4%.
- Adjusted net earnings increased by 13.3% in 2005.
(Figures in millions, except per-share data)
Income Statement Highlights
|
Avg. Est. |
FY 2005 |
FY 2004 |
% Change | |
|---|---|---|---|---|
|
Sales |
$51,110 |
$50,514 |
$47,348 |
+6.7% |
|
Net Profit |
-- |
$10,411 |
$8,509 |
+22.4% |
|
EPS |
$3.49 |
$3.46 |
$2.84 |
+21.8% |
Get back to basics with a look at the income statement.
Margin Checkup
|
FY 2005 |
FY 2004 |
Change | |
|---|---|---|---|
|
Gross Margin |
72.38% |
71.65% |
+0.72% |
|
Op. Margin |
25.75% |
27.13% |
-1.38% |
|
Net Margin |
20.61% |
17.97% |
+2.64% |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
Inexplicably, the company did not provide balance sheet information in its release.
Related Companies:
- Procter & Gamble (NYSE:PG)
- Amgen (NASDAQ:AMGN)
- Boston Scientific (NYSE:BSX)
- Allergan (NYSE:AGN)
- Pfizer (NYSE:PFE)
- Medtronic (NYSE:MDT)
Related Foolishness:
- Foolish Fundamentals: Margins
- Foolish Fundamentals: Return on Invested Capital
- Foolish Fundamentals: The Income Statement
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean.
At the time of publication, John Reeves had positions in Johnson & Johnson and Procter & Gamble. Pfizer is a Motley Fool Inside Value selection. Fool rules are here.
